Saad Mark E 4
4 · Axsome Therapeutics, Inc. · Filed Sep 11, 2024
Insider Transaction Report
Form 4
Saad Mark E
Director
Transactions
- Exercise/Conversion
Common Stock
2024-09-11$3.67/sh+11,016$40,429→ 21,018 total - Sale
Common Stock
2024-09-11$91.31/sh−11,016$1,005,871→ 10,002 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-11−11,016→ 0 totalExercise: $3.67From: 2015-09-16Exp: 2024-09-16→ Common Stock (11,016 underlying)
Holdings
- 300(indirect: See explanation 5 below.)
Common Stock
Footnotes (5)
- [F1]Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this month.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $90.25 and $92.90.
- [F5]Represents additional shares held indirectly by the Reporting Person prior to September 11, 2024 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.